Carolina Barroso-Garcia
Pamplona, NC, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Multitarget Approach for the Treatment of Alzheimer's Disease: Inhibition of Phosphodiesterase 9 (PDE9) and Histone Deacetylases (HDACs) Covering Diverse Selectivity Profiles.
Journal: ACS chemical neuroscience
Published: August 24, 2019
Taking Advantage of the Selectivity of Histone Deacetylases and Phosphodiesterase Inhibitors to Design Better Therapeutic Strategies to Treat Alzheimer's Disease.
Journal: Frontiers in aging neuroscience
Published: March 25, 2019
Discovery of in Vivo Chemical Probes for Treating Alzheimer's Disease: Dual Phosphodiesterase 5 (PDE5) and Class I Histone Deacetylase Selective Inhibitors.
Journal: ACS chemical neuroscience
Published: December 12, 2018
Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
Journal: European journal of medicinal chemistry
Published: December 11, 2017
Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease.
Journal: Journal of medicinal chemistry
Published: September 09, 2016
A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer's Disease Mice.
Journal: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
Published: March 07, 2016
Pharmacokinetic investigation of sildenafil using positron emission tomography and determination of its effect on cerebrospinal fluid cGMP levels.
Journal: Journal of neurochemistry
Published: September 03, 2015
Concomitant histone deacetylase and phosphodiesterase 5 inhibition synergistically prevents the disruption in synaptic plasticity and it reverses cognitive impairment in a mouse model of Alzheimer's disease.
Journal: Clinical epigenetics
Published: May 05, 2015
Phosphodiesterase inhibition in cognitive decline.
Journal: Journal of Alzheimer's disease : JAD
Published: August 16, 2014
Decreased levels of guanosine 3', 5'-monophosphate (cGMP) in cerebrospinal fluid (CSF) are associated with cognitive decline and amyloid pathology in Alzheimer's disease.
Journal: Neuropathology and applied neurobiology
Published: August 14, 2014
Insulin-like growth factor 2 reverses memory and synaptic deficits in APP transgenic mice.
Journal: EMBO molecular medicine
Published: August 08, 2014
Phosphodiesterases as therapeutic targets for Alzheimer's disease.
Journal: ACS chemical neuroscience
Published: July 11, 2012
Last Updated: 09/26/2026